Two snakebite antivenoms have potential to reduce Eswatini’s dependency upon a single, increasingly unavailable product: Results of preclinical efficacy testing
Fig 2
The titre of three antivenoms against five Eswatini venoms determined by end-point titration ELISA.
SAIMR Polyvalent (SAVP) shown in teal, Panafrican (ICP) shown in magenta, PANAF (PS&V) shown in blue, normal horse IgG shown in purple. Panel A: B. arietans. Panel B: D. polylepis. Panel C: H. haemachatus. Panel D: N. annulifera. Panel E: N. mossambica. Data points represent the mean of two replicates and error bars show the standard deviation. The vertical line at the 1 in 62,500 dilution represents the point at which Ig titres of each antivenom were compared.